Enzo Biochem Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Enzo Biochem hat ein Gesamteigenkapital von $69.0M und eine Gesamtverschuldung von $3.9M, was einen Verschuldungsgrad von 5.6% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $93.5M bzw. $24.4M.

Wichtige Informationen

5.6%

Verhältnis von Schulden zu Eigenkapital

US$3.86m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	US$57.16m
Eigenkapital	US$69.03m
Gesamtverbindlichkeiten	US$24.44m
Gesamtvermögen	US$93.47m

Jüngste Berichte zur Finanzlage

Recent updates

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

Oct 26

Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

May 18

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Jan 03

Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M

Dec 12

Enzo Biochem appoints Patricia Eckert as interim CFO

Oct 20

Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M

Oct 14

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Oct 04

Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale

Jun 27

Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

May 03

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Dec 17

Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Aug 24

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Mar 01

Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

Feb 03

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Jan 08

Enzo Biochem nabs expanded EUA nod for testing of COVID samples

Jan 04

Enzo Biochem: Betting On The Activists Now

Dec 16

Here's What We Think About Enzo Biochem's (NYSE:ENZ) CEO Pay

Dec 13

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ENZDie kurzfristigen Aktiva des Unternehmens ($75.7M) übersteigen seine kurzfristigen Passiva ($21.7M).

Langfristige Verbindlichkeiten: ENZDie kurzfristigen Vermögenswerte des Unternehmens ($75.7M) übersteigen seine langfristigen Verbindlichkeiten ($2.8M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ENZ über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: ENZDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 5.2% auf 5.6% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: ENZ auf der Grundlage seines derzeitigen freien Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: ENZ verfügt über eine ausreichende Liquiditätsreserve für 1 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 34.5% pro Jahr abnimmt.

Enzo Biochem Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Enzo Biochem, Inc. announced delayed annual 10-K filing

Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

Recent updates

Third quarter 2024 earnings released: US$0.042 loss per share (vs US$0.31 loss in 3Q 2023)

Second quarter 2024 earnings released: US$0.017 loss per share (vs US$0.059 loss in 2Q 2023)

Enzo Biochem, Inc. Appoints Kara Cannon to Serve as the Chief Executive Officer

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2024

Enzo Biochem, Inc. announced delayed annual 10-K filing

Enzo Biochem, Inc. Appoints Steven J. Pully to its Board of Directors

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved

High number of new and inexperienced directors

Enzo Biochem, Inc. Announces CEO Changes

Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly?

Enzo Biochem, Inc. Provides Earnings Guidance for the Years 2023, 2024, 2025, 2026 and 2027

Second quarter 2023 earnings released: US$0.23 loss per share (vs US$0.055 loss in 2Q 2022)

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.048 loss in 1Q 2022)

Enzo Biochem Non-GAAP EPS of -$0.18, revenue of $18.28M

Enzo Biochem, Inc. to Report Q1, 2023 Results on Dec 12, 2022

CEO & Director recently bought US$197k worth of stock

Insider recently bought US$5.0m worth of stock

High number of new and inexperienced directors

Enzo Biochem, Inc., Annual General Meeting, Jan 31, 2023

Enzo Biochem, Inc. Announces Resignation of David Bench as Senior Vice President, Treasurer and Corporate Secretary, Effective November 14, 2022

Enzo Biochem appoints Patricia Eckert as interim CFO

Full year 2022 earnings released

Enzo Biochem Non-GAAP EPS of -$0.17, revenue of $20.28M

Enzo Biochem, Inc. to Report Q4, 2022 Results on Oct 14, 2022

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

Enzo Biochem, Inc. Launches Ampiview Gene Expression Platform with First Products Targeting Detection of HPV and Sars-Cov-2

Enzo Biochem, Inc. to Launch Monkeypox Testing Services This Week

Enzo Biochem, Inc. Announces Executive Changes

Independent Director recently bought US$264k worth of stock

Enzo Biochem: Activist Pressure Could Finally Lead To A Company Sale

Independent Director recently bought US$276k worth of stock

Third quarter 2022 earnings released: US$0.10 loss per share (vs US$0.041 profit in 3Q 2021)

Enzo Biochem, Inc. to Report Q3, 2022 Results on Jun 09, 2022

Is Enzo Biochem (NYSE:ENZ) Using Debt In A Risky Way?

High number of new and inexperienced directors

Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test

Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022

Enzo Biochem, Inc., Annual General Meeting, Apr 08, 2022

Enzo Biochem, Inc. Appoints David Bench and Kara Cannon to New Executive Management Positions

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Enzo Biochem, Inc. Announces Resignation of Barry Weiner as President, Effective April 19, 2022

High number of new and inexperienced directors

Less than half of directors are independent

Insider recently bought US$2.5m worth of stock

Is Enzo Biochem (NYSE:ENZ) A Risky Investment?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently bought US$1.5m worth of stock

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS US$0.16 (vs US$0.60 loss in FY 2020)

Insider recently bought US$2.5m worth of stock

Health Check: How Prudently Does Enzo Biochem (NYSE:ENZ) Use Debt?

Enzo Biochem, Inc.(NYSE:ENZ) dropped from Russell 3000E Value Index

Third quarter 2021 earnings released: EPS US$0.041 (vs US$0.21 loss in 3Q 2020)

Enzo Biochem, Inc. Rejects Elazar Rabbani’s Previous Tender of Resignation as a Director

Second quarter 2021 earnings released: EPS US$0.048 (vs US$0.16 loss in 2Q 2020)

Enzo Biochem, Inc. Announces Resignation of Elazar Rabbani as CEO

Enzo Announces Its Genflex Molecular Test Detects Current Covid-19 Variants

Enzo Biochem, Inc. to Report Q2, 2021 Results on Mar 15, 2021

Does Enzo Biochem (NYSE:ENZ) Have A Healthy Balance Sheet?

New 90-day high: US$3.25

Enzo Biochem, Inc. Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin

Is Enzo Biochem, Inc. (NYSE:ENZ) Popular Amongst Insiders?

Enzo Biochem's Board of Directors Forms New Corporate Development and Planning & Succession Committees

If You Had Bought Enzo Biochem's (NYSE:ENZ) Shares Three Years Ago You Would Be Down 66%

Enzo Biochem Receives FDA Emergency Use Authorization for Testing Pooled Samples on Three Platforms Including company’s GENFLEX™ Proprietary System for Detection of Coronavirus SARS-Cov-2

New 90-day high: US$2.66

Enzo Biochem nabs expanded EUA nod for testing of COVID samples

Enzo Biochem: Betting On The Activists Now